Login / Signup

Phase III, randomised, double-blind, placebo-controlled, multicentre trial to evaluate the efficacy and safety of rhGAD65 to preserve endogenous beta cell function in adolescents and adults with recently diagnosed type 1 diabetes, carrying the genetic HLA DR3-DQ2 haplotype: the DIAGNODE-3 study protocol.

Johnny LudvigssonLinnea ErikssonChristoph NowakPedro F TeixeiraMartina WidmanAnton LindqvistRosaura CasasMarcus LindUlf Hannelius
Published in: BMJ open (2022)
EudraCT identifier: 2021-002731-32, NCT identifier: NCT05018585.
Keyphrases